Anticancer Drugs Mogamulizumab Oncology Pharmacology Physiotherapy

Mogamulizumab (Mechanism of Action)

In this article we will discuss Mogamulizumab (Mechanism of Action)

In this article, we will discuss Mogamulizumab (Mechanism of Action). So, let’s get started.

Mechanism of Action

Mogamulizumab-kpkc is a defucosylated, humanized IgG1 kappa monoclonal antibody that binds to CCR4, a G protein-coupled receptor for CC chemokines that is involved in the trafficking of lymphocytes to various organs. Non-clinical in vitro studies demonstrate mogamulizumab-kpkc binding targets a cell for antibody-dependent cellular cytotoxicity (ADCC) resulting in depletion of the target cells. CCR4 is expressed on the surface of some T-cell malignancies and is expressed on regulatory T-cells (Treg) and a subset of Th2 T-cells.


Mogamulizumab-kpkc exposure-response relationships and the time course of
pharmacodynamics response are unknown.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.